743,548 Shares in Icon Plc $ICLR Purchased by Van Lanschot Kempen Investment Management N.V.

Van Lanschot Kempen Investment Management N.V. acquired a new position in Icon Plc (NASDAQ:ICLR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 743,548 shares of the medical research company’s stock, valued at approximately $135,489,000. Icon makes up approximately 1.2% of Van Lanschot Kempen Investment Management N.V.’s holdings, making the stock its 24th biggest position. Van Lanschot Kempen Investment Management N.V. owned about 0.92% of Icon at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ICLR. WINTON GROUP Ltd purchased a new position in Icon in the second quarter worth about $254,000. Daiwa Securities Group Inc. boosted its position in Icon by 19.3% in the second quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock worth $4,094,000 after purchasing an additional 4,546 shares during the last quarter. Frontier Capital Management Co. LLC boosted its position in Icon by 97.6% in the second quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock worth $10,379,000 after purchasing an additional 35,253 shares during the last quarter. Peapack Gladstone Financial Corp purchased a new position in Icon in the second quarter worth about $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Icon by 58.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after purchasing an additional 289 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

Icon Stock Down 2.5%

ICLR stock opened at $146.18 on Friday. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.31. The stock has a market cap of $11.19 billion, a P/E ratio of 23.73, a PEG ratio of 11.84 and a beta of 1.26. The business’s 50-day moving average price is $121.76 and its 200-day moving average price is $140.47.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, June 17th. The medical research company reported $2.52 earnings per share for the quarter, beating analysts’ consensus estimates of $2.47 by $0.05. Icon had a return on equity of 9.50% and a net margin of 5.98%.The firm had revenue of $2.11 billion for the quarter, compared to analysts’ expectations of $1.99 billion. During the same period in the previous year, the firm earned $3.43 EPS. The business’s quarterly revenue was up 2.5% on a year-over-year basis. On average, equities research analysts forecast that Icon Plc will post 9.74 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Bank of America reissued an “outperform” rating on shares of Icon in a research report on Monday, June 1st. Robert W. Baird set a $119.00 target price on Icon in a research report on Friday, February 13th. JPMorgan Chase & Co. raised their target price on Icon from $120.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, May 29th. Leerink Partners set a $145.00 target price on Icon in a research report on Thursday, May 28th. Finally, Barclays raised their target price on Icon from $120.00 to $150.00 and gave the stock an “equal weight” rating in a research report on Friday, May 29th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Icon presently has an average rating of “Hold” and a consensus price target of $156.44.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.